Integrated analysis reveals the potential of cluster of differentiation 86 as a key biomarker in high-grade glioma
Open Access
- 26 December 2023
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 15 (24) , 15402-15418
Abstract
This study aimed to evaluate the potential of cluster of differentiation 86 (CD86) as a biomarker in high-grade glioma (HGG). The TCGA and TCIA databases were used to obtain the CD86 expression value, clinical data, and MRI images of HGG patients. Prognostic values were assessed by the Kaplan-Meier method, Receiver operating characteristic curve (ROC), Cox regression, logistic regression, and nomogram analyses. CD86-associated pathways were also explored. We found that CD86 was significantly upregulated in HGG compared with the normal group. Survival analysis showed a significant association between CD86 high expression and shorter overall survival time. Its independent prognostic value was also confirmed. These results suggested the possibility of CD86 as a biomarker in HGG. We also innovatively established 2 radiomics models with Support Vector Machine (SVM) and Logistic regression (LR) algorithms to predict the CD86 expression. The 2 models containing 5 optimal features by SVM and LR methods showed similar favorable performance in predicting CD86 expression in the training set, and their performance were also confirmed in validation set. These results indicated the successful construction of a radiomics model for non-invasively predicting biomarker in HGG. Finally, pathway analysis indicated that CD86 might be involved in the natural killer cell-mediated cytotoxicity in HGG progression.Keywords
This publication has 34 references indexed in Scilit:
- Immunotherapy for glioma: Current management and future applicationCancer Letters, 2020
- Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profilesBiomedicine & Pharmacotherapy, 2020
- A radiomics nomogram based on multiparametric MRI might stratify glioblastoma patients according to survivalEuropean Radiology, 2019
- Distinct Role of CD86 Polymorphisms (rs1129055, rs17281995) in Risk of Cancer: Evidence from a Meta-AnalysisPLOS ONE, 2014
- CD86 Is an Activation Receptor for NK Cell Cytotoxicity against Tumor CellsPLOS ONE, 2013
- CD86 and IL-12p70 Are Key Players for T Helper 1 Polarization and Natural Killer Cell Activation by Toll-Like Receptor-Induced Dendritic CellsPLOS ONE, 2012
- Natural killer cell line YT exerts cytotoxicity against CD86+ myeloma cells.2011
- Human Autologous In Vitro Models of Glioma Immunogene Therapy Using B7-2, GM-CSF, and IL12Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2002
- The Expression of LFA-1,ICAM-1,CD80 and CD86 Molecules in Lupus Patiens: Implication for Immunotherapy.Internal Medicine, 1999
- CD80 (B7-1) and CD86 (B7-2): Potential targets for immunotherapy?Research in Immunology, 1995